Attached files
| file | filename |
|---|---|
| EX-99 - PRESS RELEASE ISSUED BY DARA BIOSCIENCES, INC. ON OCTOBER 2, 2012 - Midatech Pharma US Inc. | rrd357370_38538.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): 10/01/2012
DARA BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
Commission File Number: 0-19140
|
Delaware
|
04-3216862
|
|
|
(State or other jurisdiction of
|
(IRS Employer
|
|
|
incorporation)
|
Identification No.)
|
8601 Six Forks Road, Suite 160
Raleigh, North Carolina 27615
(Address of principal executive offices, including zip code)
(919) 872-5578
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01. Regulation FD Disclosure
On October 2, 2012, DARA BioSciences, Inc, (the "Company") reported that on October 1, 2012, NASDAQ notified the Company that it has regained compliance with Rule 5550(a)(2), which requires a minimum bid price of $1.00 for continued listing on the NASDAQ Stock Market (the "Minimum Bid Price Rule").
The Company further announced that in light of the Company's regaining compliance with the Minimum Bid Price Rule, the special meeting of stockholders that was scheduled to take place on November 8, 2012 to consider a reverse stock split proposal has been cancelled.
On October 2, 2012, the Company issued a press release, a copy of which is being furnished as Exhibit 99 to this Report on Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
DARA BIOSCIENCES, INC.
|
||||||||
|
Date: October 02, 2012
|
By:
|
/s/ David J. Drutz
|
||||||
|
David J. Drutz
|
||||||||
|
Chief Executive Officer
|
||||||||
EXHIBIT INDEX
|
Exhibit No.
|
Description
|
|
|
EX-99.
|
Press Release Issued by DARA BioSciences, Inc. on October 2, 2012
|